Predictive Factors Associated with Naloxone Prescription among Pregnant People Admitted for the Management of Opioid Use Disorder

Abstract

Objective Our objective was to examine the biomedical and sociodemographic factors associated with the prescription of naloxone among pregnant people with opioid-use disorder (OUD) who were admitted for initiation of medications for OUD (i.e., buprenorphine-containing medications or methadone) following the implementation of a statewide initiative focused on reducing adverse perinatal health outcomes.

Study Design This is a single-site, retrospective cohort study of pregnant people admitted for the management of OUD at an urban, tertiary care center between 2013 and 2020. The primary outcome is evidence of a prescription of naloxone, ascertained from the electronic medical record. Bivariate and multivariable logistic regression modeling was performed to evaluate biomedical and sociodemographic variables associated with a prescription for naloxone. Covariates for inclusion in the multivariate logistic regression model were selected based on a p < 0.05 on bivariate analysis. Statistical significance was set at p < 0.05.

Results One hundred and thirty-nine participants met the inclusion criteria. On bivariate analysis, people who received naloxone were more likely to be admitted after the initiation of a statewide initiative focused on reducing adverse perinatal outcomes associated with perinatal OUD. Those individuals reporting intravenous drug use (IVDU) were less likely to receive naloxone. On multivariate logistic regression, after controlling for IVDU and epoch of admission, both IVDU (adjusted odds ratio [aOR]: 0.27, 95% confidence interval [CI]: 0.11–0.70) and epoch of admission (aOR: 3.48, 95% CI: 1.28–9.50) were independently associated with receipt of prescription of take-home naloxone.

Conclusion Naloxone prescription was independently associated with the epoch of admission and route of drug administration. These data can be useful in the evaluation and development of clinical practices to increase rates of naloxone prescription in pregnant people with OUD admitted for inpatient management.

Key Points

• Thirty four percent of individuals with perinatal OUD were prescribed take-home naloxone (THN).

• Epoch of admission and route of drug administration were independently associated with THN.

• These data can be used to guide public health and clinical programming for pregnant people.

Keywords

naloxone - opioid-use disorder - perinatal quality collaborative - IV drug use

Publication History

Received: 05 April 2022

Accepted: 01 November 2022

Accepted Manuscript online:
09 November 2022

Article published online:
07 December 2022

• References

• 1 Schiff DM, Nielsen T, Terplan M. et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol 2018; 132 (02) 466-474
• 2 Gemmill A, Kiang MV, Alexander MJ. Trends in pregnancy-associated mortality involving opioids in the United States, 2007-2016. Am J Obstet Gynecol 2019; 220 (01) 115-116
• 3 Moustaqim-Barrette A, Dhillon D, Ng J. et al. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. BMC Public Health 2021; 21 (01) 597
• 4 Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know. Addict Sci Clin Pract 2017; 12 (01) 4
• 5 Illinois Perinatal Quality Collaborative—Mothers and Newborns Affected by Opioids (MNO) - OB initiative. Accessed September 22, 2021 at: https://ilpqc.org/
• 6 Bedrick BS, O'Donnell C, Marx CM. et al. Barriers to accessing opioid agonist therapy in pregnancy. Am J Obstet Gynecol MFM 2020; 2 (04) 100225